Traumatic Pain is an indication for drug development with over 130 pipeline drugs currently active. According to GlobalData, preregistered drugs for Traumatic Pain have a 72.73% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Traumatic Pain compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Traumatic Pain overview
Traumatic pain arises from physical injuries or trauma to the body, typically resulting from accidents, falls, sports injuries, or surgeries. It encompasses acute pain that occurs immediately after the injury and can persist during the healing process. The intensity and duration of traumatic pain vary depending on the extent and severity of the injury. It’s often characterized by sharp, localized sensations and can involve associated symptoms like swelling, bruising, or limited mobility. Diagnosis involves assessing the injury, medical imaging, and clinical evaluations. Treatment approaches aim to manage pain, facilitate healing, and may include pain-relieving medications, physical therapy, rest, and sometimes surgical interventions for severe injuries.
For a complete picture of PTSR and LoA scores for drugs in Traumatic Pain, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
